# Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma

> **NCT04397679** · PHASE1 · TERMINATED · sponsor: **Barbara Ann Karmanos Cancer Institute** · enrollment: 2 (actual)

## Conditions studied

- Glioblastoma
- Gliosarcoma

## Interventions

- **RADIATION:** 3-Dimensional Conformal Radiation Therapy
- **RADIATION:** Intensity-Modulated Radiation Therapy (IMRT)
- **DRUG:** Temozolomide
- **DRUG:** Chloroquine
- **PROCEDURE:** Tumor Treating Fields Therapy (TTF)

## Key facts

- **NCT ID:** NCT04397679
- **Lead sponsor:** Barbara Ann Karmanos Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-12
- **Primary completion:** 2024-05-14
- **Final completion:** 2024-05-14
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2025-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04397679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04397679, "Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04397679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*